HP and Parkinson disease: GI αSyn pathology, barrier dysfunction, and gut dysbiosis offer a window into the prodromal phase of PD, sparking interest in identifying early biomarkers of GBA dysfunction, such as altered SCFA levels, increased fecal zonulin (intestinal permeability marker), or loss of butyrate-producing bacteria, that could stratify PD risk or monitor therapeutic response.